Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
Holding OVID?
Track your performance easily
OVID Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.68 - $4.10
Previous Close$1.03
Volume332.42K
Average Volume (3M)182.97K
Market Cap
$73.14M
Enterprise Value$25.50M
Total Cash (Recent Filing)$62.71M
Total Debt (Recent Filing)$15.07M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 17, 2025EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding71,009,866
10 Day Avg. Volume236,712
30 Day Avg. Volume182,967
Standard Deviation0.21
R-Squared0.00505
Alpha0.00495
Financial Highlights & Ratios
Price to Book (P/B)0.96
Price to Sales (P/S)115.81
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue40.38
Enterprise Value/Gross Profit65.11
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$3.75Price Target Upside257.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ovid Therapeutics News
PremiumCompany Announcements
Ovid Therapeutics Elevates Meg Alexander to President and COO
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 1 multiple ascending dose study of OV888 showed good safety and target engagement.
Drug DevelopmentOVID's next-generation GABA modulators, OV329 and OV350, have the potential to address a broader patient population beyond DEEs due to their differentiated safety profile and validated mechanisms of action.
Financial PerformanceThe current valuation of OVID is considered significantly undervalued, especially in light of Lundbeck's acquisition of Longboard for approximately $2.5B.
Bears Say
Clinical Trial OutcomesTakeda-partnered soticlestat missed in both of its Phase 3 studies, one in Dravet Syndrome and the other in Lennox-Gastaut Syndrome.
Clinical TrialsThe initiation of the Phase 2 proof-of-concept study of OV888 was paused to evaluate clinical design learnings from competitor programs.
Research And DevelopmentTakeda reported that soticlestat's pivotal trials in 144 Dravet syndrome and 270 Lennox-Gastaut Syndrome patients failed to reach their primary endpoints.
---
Ownership Overview
9.55% Insiders
8.05% Mutual Funds
30.63% Other Institutional Investors
42.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.68 and its highest was $4.10 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Currently, no data Available
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Mar 17, 2025 which is in 86 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Nov 12, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.207 by $0.007.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -$0.17.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 71,009,865 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.207. Following the earnings report the stock price went down -8.824%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Among the largest hedge funds holding Ovid Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Ovid Therapeutics Inc’s shares valued at 2M.
---
Ovid Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.75 (257.14% Upside)
$3.75 (257.14% Upside)
Blogger Sentiment
Neutral
OVID Sentiment 50%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.88%
12-Months-Change
Fundamentals
Return on Equity
-36.60%
Trailing 12-Months
Asset Growth
-17.90%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
---
OVID Stock 12 Month Forecast
Average Price Target
$3.75
▲(257.14% Upside)
Technical Analysis
Best Analysts Covering OVID
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+47.79%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +47.79% per trade.
---